NCT07634562
TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation
Not Yet Recruiting
PHASE1Ages 18–55InterventionalTreatmentStanford UniversityInvestigator-initiated
~12 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Anti-Thymocyte Globulin, ATG (Rabbit)Total lymphoid irradiation
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The success rate
Measured over After intervention through 18 months and monitored monthly up to 36 months.
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Stephan Busque, MD, MSc · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Undergoing liver transplantation at Stanford University
No contraindications to Total Lymphoid Irradiation or rabbit antithymocyte globulin (rATG)
Exclusion
Contraindications to Total Lymphoid Irradiation (e.g. pregnancy, bone marrow suppression or disease, autoimmune disease, prior radiation in the field)
Contraindications to rATG
Patients with history of hepatocellular carcinoma (HCC) or other malignancies with exception of non melanoma skin cancer in remission Model of End-Stage Liver Disease (MELD) score \> 25 Liver transplants with severe reperfusion syndrome (hemodynamic instability requiring 3 or more pressors after reperfusion) Liver transplant with early allograft dysfunction (Orloff criteria) Diagnosis of hepatitis B Diagnosis of hepatitis C, except for patients that have been treated and eradicated of hepatitis C Virtual and/or flow crossmatch positive (MFI added up to 8000 for each DSA with MFI\>1000).
What this trial measures
- The success rateAfter intervention through 18 months and monitored monthly up to 36 months.
The success rate is defined as the percentage of participants free from all immunosuppressive drugs by 18 months after the start of the conditioning regimen). This will be estimated with standard errors by the Kaplan-Meier procedure and the Greenwood formula.